A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...

Spravato is made from esketamine, one of two mirror-image molecules found in ... The original approval required that patients on Spravato also receive an oral antidepressant. Now, the FDA says the ...

The US Food and Drug Administration (FDA) has approved the use of esketamine nasal spray as a standalone treatment for adults with major depressive disorder (MDD) who have not responded adequately ...

The FDA has approved Janssen’s antidepressant ... who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster for Janssen ...

“Hopefully, this approval by the FDA shows that there is sufficient evidence for esketamine working that providers and patients and their families will be comfortable and more confident that in ...

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

Alert FDA OKs Esketamine Nasal Spray Monotherapy for Depression The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not responded ...

For the first time, the U.S. Food and Drug Administration (FDA) has approved the use of a ketamine-like drug as a stand-alone therapy for adults with treatment-resistant depression (TRD).

Spravato is made from esketamine, one of two mirror-image molecules ... on Spravato also receive an oral antidepressant. Now, the FDA says the drug can be used on its own. The decision came ...